Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Women undergoing cesarean section delivery.~2. Patients classified as American Society of Anesthesiology (ASA) class II or III.~   1. ASA II: mild systemic disease, pregnancy~  2. ASA III: severe systemic disease~3. Women ≥ 18 years old~4. Neuraxial anesthesia (spinal) to be used as anesthetic technique intraoperatively for cesarean section (this is the UAB Anesthesiology standard of care).~Exclusion Criteria:~1. Any patient not classified as an ASA I or II.~2. General Anesthesia or neuraxial anesthesia with epidural used as anesthetic techniques for cesarean section.~3. Allergy/intolerance to local anesthetic or steroids.~4. Pre-existing neurological and/or anatomical deficit that would preclude regional block.~5. Coexisting coagulopathy such as hemophilia or von Willebrand Disease~6. BMI \> 40.~7. Emergency Cesarean Sections

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): 20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine.
- 2mg Dexamethasone (Type: ACTIVE_COMPARATOR): 20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine.
- 4mg Dexamethasone (Type: ACTIVE_COMPARATOR): 20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine.

Based on this trial design, predict the completion outcome and termination type (if applicable).